Le Lézard
Classified in: Health, Business
Subject: VEN

NeuroDex, Inc. and ICV Venture Engineering Fund Announce Closing of Seed Round for NeuroDex, Inc.


NATICK, Mass., April 2, 2020 /PRNewswire/ -- NeuroDex, Inc. ("NeuroDex" or "Company"), a developer of diagnostics, theranostics, prognostics, and pharmacodynamic analysis in the neurology space, announces that the Company has completed its seed round of financing, led by ICV Venture Engineering Fund I, LLC ("ICV"), in accordance with an agreement signed between NeuroDex and ICV in January 2020.

"We appreciate the confidence ICV has placed in us and believe that this capital will be instrumental to NeuroDex building out, expanding, and streamlining our unique ExoSORTtm technology," noted Oded Biran, Co-Founder and Chief Executive Officer of NeuroDex. "The solidification of our relationship with ICV will allow us access to ICV's unique experience and expertise, as well as its various other resources, all of which will advance our development and grant significant benefits to all of our stakeholders," added Mr. Biran.  

"We're excited to lead the seed round for NeuroDex. We have been impressed by what the team accomplished in the short period of time since NeuroDex's inception and look forward to supporting their vision to produce an Exosome-of-origin based toolbox. This is another example of our focus on investing in the leading, upstart companies across the life sciences spectrum," said Gary Magnant, a Partner in ICV.

The commercial terms of the round remain confidential.

About NeuroDex

NeuroDex is a leading developer of exosome-of-origin based diagnostics. NeuroDex's integrative research platform, called ExoSORTtm, combines bioinformatics and state-of-the-art laboratory processes. Building on all of its proprietary platform technologies (including ExoSORTtm), NeuroDex develops a full range of exosome-of-origin, minimally invasive, blood-based diagnostic, prognostic, pharmacodynamic, and theranostic tools. For more information, visit www.neurodex.co.

About ICV

ICV Venture Engineering Fund I, LLC is a pre-seed and seed-stage fund focused on Massachusetts-based emerging life science technologies and companies that have the potential to transformatively or disruptively change the markets they address. For more information, contact [email protected]

Forward-Looking Statement Disclaimer

Various statements in this release concerning NeuroDex's, or ICV's future expectations, plans and prospects, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors. In addition, any forward-looking statements represent NeuroDex's, or ICV's views only as of the date of this release and should not be relied upon as representing their views as of any subsequent date. NeuroDex and ICV do not assume any obligation to update any forward-looking statements unless required by law.

NeuroDex Contact:                                       

Oded Biran, CEO                               

[email protected]

ICV Contact:                                      

Gary Magnant, Partner

[email protected]

SOURCE NeuroDex, Inc.


These press releases may also interest you

at 22:18
The report titled "Personalized Nutrition Market by Measurement Type (Active Measurement, Standard Measurement), Application (Indication-based, Standard Supplements), Distribution Channel, End-Use - Global Forecast 2024-2030" is now available on...

at 22:03
The report titled "Carbon Dioxide Incubator Market by Product (Air Jacketed CO2 Incubators, Direct Heat CO2 Incubators, Water Jacketed CO2 Incubators), Capacity (100-200 Litre, Above 200 Litre, Below 100 Litre), Application, End User - Global...

at 22:00
The "Global Clinical In Vitro Diagnostic Medical Laboratory Services Market: Strategy & Trends with Volume & Price Forecasts by Chemistry, Hematology, Microbiology, Pathology, Covid-19, and Molecular Dx by Country. Updated with Impact of COVID-19"...

at 21:45
The "Molecular Diagnostics at the Point of Care. By Application, Technology, Place, Product and by Country. With Executive Guides and Customization 2023 - 2027 " report has been added to  ResearchAndMarkets.com's offering. Infectious disease Dx is...

at 21:30
The "Whole Genome and Exome Sequencing Markets by Application, Organism and Product with Executive and Consultant Guides. Includes Direct to Consumer Analysis. 2023 to 2027" report has been added to  ResearchAndMarkets.com's offering. Will all...

at 20:50
Pharma (1167.HK), a clinical-stage oncology company drugging the undruggable targets, today announced its 2023 annual results. The revenue was RMB63.5 million, the R&D investment was RMB372 million, the cash and cash equivalent at the end of 2023 was...



News published on and distributed by: